Afinitor: Medgend

Afinitor FDA Approved Drugs

AFINITOR [Everolimus^{C₅₃H₈₃NO₁₄}]

10mg (oral tablet)

2.5mg (oral tablet)

7.5mg (oral tablet)

Novartis^{Mar 30, 2009}

Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic.
Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected..
Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib.

efficacy
2.0 (2)

side effects
0.0 (0)

danger
0.0 (0)

AFINITOR DISPERZ [Everolimus^{C₅₃H₈₃NO₁₄}]

2mg (oral tablet, for suspension)

3mg (oral tablet, for suspension)

5mg (oral tablet, for suspension)

Novartis Pharm^{Aug 29, 2012}

Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected..

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ZORTRESS [Everolimus^{C₅₃H₈₃NO₁₄}]

0.25mg (oral tablet)

0.5mg (oral tablet)

0.75mg (oral tablet)

Novartis^{Apr 20, 2010}

Prophylaxis of allograft rejection in adult patients receiving a liver transplant.
Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.